Mostrar el registro sencillo del ítem
dc.contributor.author | Vicent, Lourdes | |
dc.contributor.author | Esteban Fernández, Alberto | |
dc.contributor.author | Gómez Bueno, Manuel | |
dc.contributor.author | Juan Bagudá, Javier de | |
dc.contributor.author | Díez Villanueva, Pablo | |
dc.contributor.author | Iniesta, Ángel Manuel | |
dc.contributor.author | Ayesta, Ana | |
dc.contributor.author | González Saldivar, Hugo | |
dc.contributor.author | Rojas González, Antonio | |
dc.contributor.author | Bover Freire, Ramón | |
dc.contributor.author | Iglesias del Valle, Diego | |
dc.contributor.author | García Aguado, Marcos | |
dc.contributor.author | Perea Egido, Jesus Ángel | |
dc.contributor.author | Martínez Sellés Oliveria Soares, Manuel | |
dc.date.accessioned | 2019-05-12T18:24:11Z | |
dc.date.available | 2019-05-12T18:24:11Z | |
dc.date.issued | 2019 | |
dc.identifier.citation | Vicent, L., Esteban-Fernández, A., Gómez-Bueno, M., De-Juan, J., Díez-Villanueva, P., Iniesta, Á. M., ... & Iglesias, D. (2019). Sacubitril/valsartan in daily clinical practice: data from a prospective registry. Journal of Cardiovascular Pharmacology, 73(2), 118-124. https://doi.org/10.1097/FJC.0000000000000641 | spa |
dc.identifier.issn | 0160-2446 | |
dc.identifier.issn | 1533-4023 | |
dc.identifier.uri | http://hdl.handle.net/11268/7890 | |
dc.description.abstract | Sacubitril/valsartan (SV) is a new therapy in heart failure with reduced ejection fraction. Our aim was to determine the efficacy and safety of this drug daily clinical practice. We performed a multicenter registry in 10 hospitals. All patients who started SV from October 2016 to March 2017 on an outpatient basis were included. A total of 427 patients started treatment with SV. Mean follow-up was 7.0 ± 0.1 months. Forty-nine patients (11.5%) discontinued SV, and 12 (2.8%) died. SV discontinuation was associated with higher cardiovascular (hazard ratio 13.22, 95% confidence interval, 6.71-15.73, P < 0.001) and all-cause mortality (hazard ratio 13.51, 95% confidence interval 3.22-56.13, P < 0.001). Symptomatic hypotension occurred in 71 patients (16.6%). Baseline N-terminal pro-B-type natriuretic peptide levels, functional class, and left ventricular ejection fraction improved at the end of follow-up in patients who continued with SV (all P values ≤0.001). This improvement was not significant in patients with SV discontinuation. SV has a good tolerability in patients from daily clinical practice. SV withdrawal in patients with heart failure and reduced ejection fraction was independently associated with increased all-cause mortality. Patients who continued with SV presented an improvement in functional class left ventricular ejection fraction and N-terminal pro-B-type natriuretic peptide levels. | spa |
dc.description.sponsorship | Sin financiación | spa |
dc.language.iso | eng | spa |
dc.title | Sacubitril/Valsartan in Daily Clinical Practice: Data From a Prospective Registry | spa |
dc.type | article | spa |
dc.description.impact | 2.598 JCR (2019) Q2, 62/138 Cardiac & Cardiovascular Systems; Q3, 147/270 Pharmacology & Pharmacy | spa |
dc.description.impact | 0.800 SJR (2019) Q2, 110/362 Cardiology and Cardiovascular Medicine, 112/331 Pharmacology | spa |
dc.description.impact | No data IDR 2019 | spa |
dc.identifier.doi | 10.1097/FJC.0000000000000641 | |
dc.rights.accessRights | closedAccess | spa |
dc.subject.uem | Insuficiencia cardíaca | spa |
dc.subject.uem | Terapéutica | spa |
dc.subject.unesco | Enfermedad cardiovascular | spa |
dc.subject.unesco | Tratamiento médico | spa |
dc.subject.unesco | Medicamento | |
dc.description.filiation | UEM | spa |
dc.peerreviewed | Si | spa |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |